NLS Pharmaceutics Ltd (NASDAQ:NLSP)’s traded shares stood at 0.11 million during the last session, with the company’s beta value hitting 0.17. At the close of trading, the stock’s price was $2.44, to imply a decrease of -5.06% or -$0.13 in intraday trading. The NLSP share’s 52-week high remains $15.59, putting it -538.93% down since that peak but still an impressive 46.72% since price per share fell to its 52-week low of $1.30. The company has a valuation of $8.78M, with an average of 0.4 million shares in intraday trading volume over the past 10 days and average of 287.66K shares over the past 3 months.
Analysts have given a consensus recommendation of Buy for NLS Pharmaceutics Ltd (NLSP), translating to a mean rating of 3.00. Of 2 analyst(s) looking at the stock, 0 analyst(s) give NLSP a Sell rating. 0 of those analysts rate the stock as Overweight while 0 advise Hold as 2 recommend it as a Buy. 0 analyst(s) have given it an Underweight rating. Estimates put the company’s current-quarter earnings per share at 0.
NLS Pharmaceutics Ltd (NASDAQ:NLSP) trade information
After registering a -5.06% downside in the last session, NLS Pharmaceutics Ltd (NLSP) has traded red over the past five days. The 5-day price performance for the stock is -3.94%, and 15.64% over 30 days. With these gigs, the year-to-date price performance is -68.93%. Short interest in NLS Pharmaceutics Ltd (NASDAQ:NLSP) saw shorts transact 72299.0 shares and set a 0.15 days time to cover.
NLSP Dividends
NLS Pharmaceutics Ltd has its next earnings report out in August. However, it is important to take into account that this dividend yield ratio is just an indicator to only serve the purpose of guidance. Investors interested to invest in the stock should ponder company’s other fundamental and operations related aspects too.
NLS Pharmaceutics Ltd (NASDAQ:NLSP)’s Major holders
NLS Pharmaceutics Ltd insiders hold 32.46% of total outstanding shares, with institutional holders owning 10.04% of the shares at 14.86% float percentage. In total, 10.04% institutions holds shares in the company, led by BVF INC/IL. As of 2024-06-30, the company held over 5.75 million shares (or 15.0543% of shares), all amounting to roughly $1.25 million.
The next major institution holding the largest number of shares is ARMISTICE CAPITAL, LLC with 2.31 million shares, or about 6.0535% of shares outstanding. As of the market price on 2024-06-30, these shares were worth $0.5 million.
Going by data provided on Mar 31, 2025, Fidelity Concord Street Trust-Fidelity Nasdaq Composite Index Fund holds roughly 358.0 shares. This is just over 0.01% of the total shares, with a market valuation of $873.0
